<DOC>
	<DOCNO>NCT00956254</DOCNO>
	<brief_summary>This open-label , single-dose study ass safety , tolerability , absorption/distribution kinetics single 100 µg dose fentanyl sublingual spray opioid-tolerant cancer subject , without oral mucositis .</brief_summary>
	<brief_title>Fentanyl Sublingual Spray Treating Opioid-tolerant Cancer Patients With Without Oral Mucositis</brief_title>
	<detailed_description>RATIONALE : One dose fentanyl sublingual spray may effective relieve pain opioid-tolerant cancer patient . PURPOSE : This phase III trial study side effect fentanyl sublingual spray see well work treat opioid-tolerant cancer patient without oral mucositis . OBJECTIVES : Primary - To compare absorption/distribution kinetics single dose fentanyl sublingual spray opioid-tolerant cancer patient without oral mucositis . - To evaluate safety tolerability regimen . OUTLINE : This multicenter study . Patients fast least 8 hour least 4 hour water allow least 1 hour least 1 hour study drug administration . Patients receive single dose fentanyl sublingual spray upright position clinical care recliner bed , remain upright posture least 4 hour administration . Patients instruct swallow least 5 minute administration expectorate drug . After study drug administration , 10 blood sample collect 12-hour period pharmacokinetic analysis .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer meet 1 follow criterion : Mild mucositis , define grade 1 ( erythema mucosa ) 2 ( patchy ulceration pseudomembranes ) day study drug administration . No mucositis , define normal oral cavity upon examination day study drug administration . Opioidtolerant , define patient take ≥ 60 mg oral morphine/day , ≥ 30 mg oxycodone/day , ≥ 8 mg oral hydromorphone/day , equianalgesic dose another opioid ≥ 7 day cancerrelated pain . Persistent pain related cancer treatment past 7 day . No brain metastases sign symptom increase intracranial pressure . PATIENT CHARACTERISTICS : Negative pregnancy test . Agree confine study site approximately 12 hour , eat food serve study unit study confinement period , consume food provide designated meal snack time . No history major organ system impairment disease , investigator 's his/her designee 's opinion , could increase risk associate use opioids . No uncontrolled hypertension despite antihypertensive therapy history hypertensive crisis within past 2 year . No recent history ( within past 2 year ) transient ischemic attack , neural vascular disease , stroke , cerebral aneurysm . No intolerable side effect opioids fentanyl . PRIOR CONCURRENT THERAPY : See Disease Characteristics . More 30 day since prior investigational agent . More 14 day since prior monoamine oxidase inhibitor . No prior participation either Insys Fentanyl Sublingual Spray Phase III study INSYSINS05001 INSYSINS06007 . No concurrent use fentanyl product . Patients receive Actiq® , Fentora® , Duragesic® eligible 7day washout . No concurrent medication ( prescription , overthecounter , vitamin , herbal substance ) except hormonal contraceptive and/or ≤ 3 dos acetaminophen ≤ 1 g .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>mucositis</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>pain</keyword>
</DOC>